Initial Management of Congestive Heart Failure Exacerbation

Patient Assessment and Diuretic Therapy

The American Heart Association recommends that patients admitted with congestive heart failure exacerbation and significant fluid overload should be promptly treated with intravenous loop diuretics starting in the emergency department, with the initial IV dose equaling or exceeding their chronic oral daily dose 1, 2, 3
The American College of Cardiology suggests assessing volume status, systemic perfusion, and identifying precipitating factors simultaneously with diuretic initiation 1, 2, 3
Patients should be assessed for adequacy of systemic perfusion, including signs of hypotension, cool extremities, altered mental status, and decreased urine output 1, 2
Volume status should be evaluated by assessing jugular venous pressure, pulmonary congestion, peripheral edema, and ascites 1, 2
Precipitating factors such as acute coronary syndrome, severe hypertension, arrhythmias, infections, pulmonary emboli, renal failure, or medication/dietary noncompliance should be identified 1, 2, 4

The American Heart Association recommends obtaining an electrocardiogram and cardiac troponin to identify acute coronary syndrome as a precipitating factor 1, 2, 3
A chest radiograph should be obtained to assess pulmonary congestion and cardiac silhouette 1, 2, 3
BNP or NT-proBNP should be measured when the contribution of heart failure to dyspnea is uncertain 1, 2, 3
Echocardiography should be performed to assess ejection fraction, chamber size, wall thickness, and valve function 1, 2, 3
Daily assessments should include fluid intake and output measurement, vital signs, daily weight, and clinical signs of perfusion and congestion 1, 2, 3, 5

The American College of Cardiology recommends starting IV loop diuretics within 60 minutes of presentation, with the initial dose equaling or exceeding the chronic oral daily dose 1, 2, 3, 6
For patients already on loop diuretics, the initial IV dose should equal or exceed the chronic oral daily dose 1, 2, 3, 7
The American Heart Association suggests considering the addition of a second diuretic, such as a thiazide diuretic or spironolactone, if there is an inadequate response to loop diuretics alone 1, 3, 6
IV vasodilators, such as nitroglycerin or nitroprusside, should be considered in patients with severe fluid overload without systemic hypotension 8, 9

The American College of Cardiology recommends continuing existing guideline-directed medical therapy (GDMT) in patients with reduced ejection fraction, including ACE inhibitors/ARBs and beta-blockers, unless there are contraindications or hemodynamic instability 5, 7, 4
GDMT should be initiated or optimized in patients with reduced ejection fraction before discharge 5, 7
Beta-blockers should be started at a low dose only after volume optimization and discontinuation of IV diuretics, vasodilators, and inotropes 5, 7, 4, 8

The American College of Cardiology recommends initiating GDMT during hospitalization once clinical stability is achieved after initial diuresis, which can often begin on day 1 if the patient is adequately perfused and not requiring inotropes 10
The European Journal of Heart Failure suggests starting SGLT2 inhibitors and MRAs first because they have the least effect on blood pressure but rapid beneficial effects, which can often be initiated on day 1 once adequate perfusion is confirmed and the patient is responding to diuretics 11

The American Heart Association, as published in Circulation, advises against starting beta-blockers on day 1 if the patient required oxygen and is acutely decompensated, and recommends initiation only after volume optimization is achieved, IV vasodilators and inotropes are discontinued, and clinical stability is confirmed 12
The European Society of Cardiology, as published in the European Journal of Heart Failure, recommends delaying ACE inhibitors/ARBs/ARNIs until volume status is optimized, no marked azotemia or hyperkalemia risk is present, and blood pressure is adequate (SBP >90-100 mmHg) 11

The American College of Cardiology recommends assessing for clinical stability, such as improved congestion, stable renal function, and adequate perfusion, before considering low-dose ACE inhibitor/ARB/ARNI initiation 10
The American Heart Association, as published in Circulation, suggests transitioning to oral diuretics when euvolemia is approached, and initiating low-dose beta-blocker only after IV therapies are discontinued and volume is optimized 12

The American College of Cardiology advises against discontinuing GDMT if mild renal function decrease or asymptomatic blood pressure reduction occurs, unless contraindicated, as this can lead to suboptimal therapy 10
The American College of Cardiology also notes that only 73% of eligible patients receive ACE inhibitors/ARBs/ARNIs, 66% receive beta-blockers, and 33% receive MRAs within 30 days post-hospitalization, highlighting the importance of initiating therapy during hospitalization 10